Abstracts - faqs.org

Abstracts

Business, general

Search abstracts:
Abstracts » Business, general

Templeton Emerging Markets Fund

Article Abstract:

A comparative analysis of the company sales and the financial details of Templeton Emerging Markets Fund, Inc. from 1988 to 2003 are illustrated. Projections of the annual total returns, revenues and asset position of this company for 2007-09 are made using Value Line estimates.

Author: Haws, Donna
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2004
United States, Sales, profits & dividends, Company sales and earnings, Company earnings/profit

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Templeton E.M

Article Abstract:

The price appreciation potential of the shares of Templeton Emerging Markets Fund Inc. for the years 2010-2012 is discussed. The St. Petersburg, Florida-based company has a portfolio of equity securities of countries with emerging economies.

Author: Greene, Robert M.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2007
Evaluation, Stocks, Stock prices

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA



Subjects list: United States, Investment companies, Securities, Company securities, Templeton Emerging Markets Fund Inc.
Similar abstracts:
  • Abstracts: Little miss marketing. Marketing reinvented. Branding value
  • Abstracts: A masterly multiplexit. The tortoise and the hare. Would u be Nickel king
  • Abstracts: Metro One Telecommunications. Citizens Communications. Metro One T'Comms
  • Abstracts: Swiss Helvetia. Templeton E.M
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.